
Marta Nyakas
- PhD student; MD
- +4722781849
Publications 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
J Immunother Cancer, 8 (1)
DOI 10.1136/jitc-2019-000391, PubMed 32503946
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
Br J Cancer, 124 (3), 574-580
DOI 10.1038/s41416-020-01121-y, PubMed 33087895
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer
Front Immunol, 11, 572172
DOI 10.3389/fimmu.2020.572172, PubMed 33324397
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
N Engl J Med, 383 (12), 1139-1148
DOI 10.1056/NEJMoa2005493, PubMed 32877599
Soluble AXL as a marker of disease progression and survival in melanoma
PLoS One, 15 (1), e0227187
DOI 10.1371/journal.pone.0227187, PubMed 31917795
BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis
Acta Oncol, 59 (7), 833-844
DOI 10.1080/0284186X.2020.1747636, PubMed 32285732
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials
JAMA Oncol, 6 (8), 1256-1264
DOI 10.1001/jamaoncol.2020.2288, PubMed 32672795
Publications 2019
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
Ann Oncol, 30 (7), 1154-1161
DOI 10.1093/annonc/mdz110, PubMed 30923820
Reply to E. Hindié and K.R. Hess
J Clin Oncol, 37 (15), 1356-1358
DOI 10.1200/JCO.19.00004, PubMed 30939092
Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
Clin Exp Immunol, 197 (1), 74-82
DOI 10.1111/cei.13283, PubMed 30821848
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Lancet Oncol, 20 (5), 701-710
DOI 10.1016/S1470-2045(18)30940-9, PubMed 30928620
Publications 2018
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
Eur J Cancer, 101, 236-243
DOI 10.1016/j.ejca.2018.06.034, PubMed 30096704
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma
J Clin Oncol, 36 (35), 3441-3449
DOI 10.1200/JCO.18.01219, PubMed 30343620
An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system
Eur J Cancer, 107, 175-185
DOI 10.1016/j.ejca.2018.11.018, PubMed 30580112
Publications 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Lancet Oncol, 18 (5), 611-622
DOI 10.1016/S1470-2045(17)30231-0, PubMed 28359784
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma
Clin Cancer Res, 23 (18), 5339-5348
DOI 10.1158/1078-0432.CCR-16-2923, PubMed 28611198
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
N Engl J Med, 377 (19), 1813-1823
DOI 10.1056/NEJMoa1708539, PubMed 28891408
Publications 2016
Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine
Case Rep Med, 2016, 9639585
DOI 10.1155/2016/9639585, PubMed 27504122
Publications 2013
A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies
Eur J Cancer, 49 (7), 1521-9
DOI 10.1016/j.ejca.2013.01.013, PubMed 23433846
Malignant melanoma--diagnosis, treatment and follow-up in Norway
Tidsskr Nor Laegeforen, 133 (20), 2154-9
DOI 10.4045/tidsskr.12.1416, PubMed 24172628
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
Lancet Oncol, 14 (8), 733-40
DOI 10.1016/S1470-2045(13)70237-7, PubMed 23735514
Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
Cancer Immunol Immunother, 62 (9), 1499-509
DOI 10.1007/s00262-013-1453-3, PubMed 23817721
Publications 2012
Improved survival with MEK inhibition in BRAF-mutated melanoma
N Engl J Med, 367 (2), 107-14
DOI 10.1056/NEJMoa1203421, PubMed 22663011
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
Br J Cancer, 106 (11), 1728-34
DOI 10.1038/bjc.2012.158, PubMed 22531637
Publications 2011
Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial
Clin Cancer Res, 17 (21), 6847-57
DOI 10.1158/1078-0432.CCR-11-1385, PubMed 21918169